- February 09, 2022
Founded in 2019, Imescia is a spin-off company from the Institut Galien Paris-Sud, co-founded by Tanguy Boissenot CEO (Pharm.D., Ph.D.), Alexandre Bordat COO (Ecole polytechnique, Ph.D.), Nicolas Tsapis (Ph.D., CNRS researcher), and Julien Nicolas (Ph.D., CNRS researcher). The company is the result of four years of fundamental research at the Institut Galien Paris-Sud. The team has the expertise in polymer synthesis and drug delivery systems. We aim to enhance the best anticancer treatments by increasing their tumor accumulation. At Imescia we tackle this problem by leveraging our unique polymer prodrug technology that allows an increased tumor accumulation of HPAPIs therefore enhancing their efficacy.